2013
DOI: 10.1016/j.jns.2012.08.030
|View full text |Cite
|
Sign up to set email alerts
|

Istradefylline, an adenosine A2A receptor antagonist, for patients with Parkinson's Disease: A meta-analysis

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
16
1

Year Published

2014
2014
2022
2022

Publication Types

Select...
6
3

Relationship

0
9

Authors

Journals

citations
Cited by 42 publications
(17 citation statements)
references
References 22 publications
0
16
1
Order By: Relevance
“…A2a antagonism/inverse agonism is clearly a promising target in the treatment of human Parkinson's disease (41), as both caffeine intake (42) and genetic polymorphisms of the Adora2a gene (43) contribute to the risk of contracting the disease. Furthermore, in the study of Parkinson's disease, promising results have been obtained with istradefylline, an inverse agonist specific to A2a (44). Thus, cyclic dinucleotides constitute a potential novel class of A2a inverse agonist, with pharmacokinetics, pharmacodynamics, and safety profiles distinctive from those of istradefylline.…”
Section: Discussionmentioning
confidence: 99%
“…A2a antagonism/inverse agonism is clearly a promising target in the treatment of human Parkinson's disease (41), as both caffeine intake (42) and genetic polymorphisms of the Adora2a gene (43) contribute to the risk of contracting the disease. Furthermore, in the study of Parkinson's disease, promising results have been obtained with istradefylline, an inverse agonist specific to A2a (44). Thus, cyclic dinucleotides constitute a potential novel class of A2a inverse agonist, with pharmacokinetics, pharmacodynamics, and safety profiles distinctive from those of istradefylline.…”
Section: Discussionmentioning
confidence: 99%
“…As in AD, there is also solid evidence for a role of A 2A R in the control of PD, as testified by the recent introduction of A 2A R antagonists as coadjuvants in the management of PD [121]. Thus, A 2A R antagonists improve PD symptoms in different rodent and primate models of the disease and also in PD patients enrolled in clinical trials (for a review see [122]).…”
Section: Introductionmentioning
confidence: 99%
“…As a result of this direct A 2A R-D 2 R interaction [29], antagonists for A 2A R have emerged as new targets for non-dopaminergic antiparkinsonian treatments [30]. Indeed, several clinical trials have shown that the administration of istradefylline (or KW-6002), an A 2A R antagonist, ameliorates the dyskinesias induced by chronic levodopa treatment of PD patients [31][32][33][34][35][36][37][38]. Similarly, since A 2A R levels have been shown to be increased in the putamen of some PD patients [5][6][7][8][9], it seems likely that ADORA2A repression would be an alternative therapy to reduce A 2A R activity.…”
Section: Resultsmentioning
confidence: 99%